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Retinal nerve ﬁbre layerRetinal nerve ﬁbre layer (RNFL) thickness and macular volume (MV) can be measured in vivo using optical
coherence tomography (OCT) providing a “window into the brain”. RNFL and MV are promising biomarkers in
neurological diseases. This study explores the potential of RNFL and MV to detect axonal abnormalities in vivo in
schizophrenia and their correlations with clinical features. OCT was performed in 49 patients (38 schizophrenia,
11 schizoaffective disorder) and 40 healthy controls matched for age and gender. Group comparisons were
made between whole retina and quadrant RNFL thickness and MV using multi-level analyses. In patients, associa-
tions were sought between RNFL and MV with symptom severity (positive/negative). Patients and controls had
similar whole retina RNFL thickness (p=0.86) andMV (p=0.64), but RNFL in the right nasal quadrant of the schi-
zoaffective group was thinner than in the schizophrenia group (p=0.02). In patients, positive symptom severity
was associated with smaller MV (right β=−0.54, p=0.02; left β=−0.49, p=0.04). Normal MV and RNFL thick-
ness suggests unmyelinated axons in patients with schizophrenia/schizoaffective disorder remain unaffected.
Longitudinal studies using higher resolution OCT will clarify whether progressive RNFL and MV changes
occur and whether they can be used as state or trait markers in schizophrenia.
© 2012 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Schizophrenia lacks a clearly deﬁned or diagnostic neuropathological
signature. The best validated neuropathological abnormalities include
possible reductions of neuronal density in the thalamus, but not in the
cerebral cortex or hippocampus, although in these structures pyramidal
neurons may have smaller bodies with reduced dendritic arborisation
and spines (Harrison and Weinberger, 2005). Reductions in the number
of some interneurons and in the number and function of oligodendro-
cytes, relevant to myelination and neuronal and synaptic integrity,
complete the picture (Harrison and Weinberger, 2005). In keeping with
these ﬁndings, neuroimaging studies have reported grey matter volume
deﬁcits in those with chronic schizophrenia (Ellison-Wright and
Bullmore, 2009), those in their ﬁrst episode of psychosis (Bangalore et
al., 2009), in a prodromal phase of illness (Pantelis et al., 2003), or at
high genetic risk of schizophrenia (Witthaus et al., 2009). Childhood
onset schizophrenia also results in progressive grey matter volume loss
in the early years of illness (Sporn et al., 2003). Compromised white
matter integrity rather than volume loss has been reported in ﬁrst
episode (Price et al., 2007) and chronic schizophrenia (Kanaan et al.,
2009).y, NMR Unit 6th Floor, Queen
1; fax: +44 207 278 5616.
Ltd. All rights reserved.Longitudinal imaging studies have also suggested that at least in
some patients there may be an accelerated loss of grey matter in com-
parison with healthy controls immediately after the ﬁrst episode of
schizophrenia (Sun et al., 2009), with similar results documented in
chronic patients (Brans et al., 2008) and in those at ultra high risk,
even before the ﬁrst episode of psychosis (Takahashi et al., 2010).
However, the precise neuropathological changes that underlie these
neuroimaging ﬁndings remain to be determined.
In vivo visualisation of the retinal nerve ﬁbre layer (RNFL) can be
achieved by optical coherence tomography (OCT), a non-invasive, fast
imaging technique used to monitor retinal changes in glaucoma
(Huang et al., 1991). There are no contra-indications to OCT, which
opens a “window into the brain” by allowing measurement of RNFL
thickness and macular volume (MV). The RNFL is composed of
unmyelinated axons that traverse the retina, with the highest axonal
density contained in the macula. OCT has recently been applied to the
study of neurological conditions with diffuse and progressive brain
pathology.
RNFL thinning has been described in patients with mild cognitive
impairment without dementia (Paquet et al., 2007). It correlates with
the severity of cognitive impairment in patients with Alzheimer's
disease (Iseri et al., 2006), and Berisha et al. (2007) have reported it
in the early stages of Alzheimer's disease. RFNL thinning is also present
in patients with Parkinson's disease, in whom loss of dopaminergic
neurons is known to occur, not only in the cortex and basal ganglia
but also in the retinal ganglion cells (Altintas et al., 2007). OCT reveals
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of optic neuritis (Trip et al., 2005). Reduced RNFL thickness is also
described in multiple sclerosis (MS), even in patients without a prior
history of optic neuritis and this correlates with magnetic resonance
imaging (MRI) measures of brain atrophy (Siger et al., 2008). In healthy
subjects, RNFL thickness has been reported to be associated with cogni-
tive performance, particularly in those below 40 years of age (van
Koolwijk et al., 2009). In glaucoma, around 20% RNFL thinning was
reported at 2-month follow-up after onset of the disease (Fang et al.,
2007), while rate of RNFL thinning in a longitudinal study of chronic
glaucoma was less than 1% a year (Leung et al., 2011).
In schizophrenia, widespread; albeit subtle, neuropathological
abnormalities, together with electroretinogram (ERG) changes indic-
ative of reduction in rod photoreceptors or changes in inter-neuronal
retinal architecture (Balogh et al., 2007), have also been described in
those at high genetic risk of schizophrenia (Hébert et al., 2009) and in
autism, (Ritvo et al., 1988). Hence there is good reason for using OCT
to search for disease biomarkers.
We present here the ﬁrst study, to our knowledge, to use OCT to
study the retina in patients with schizophrenia and schizoaffective
disorder. We hypothesised that retinal changes indicative of
schizophrenia-related neuropathology would be present and quanti-
ﬁable in our patients. We also looked for associations between OCT
ﬁndings and disease symptoms.
2. Methods
2.1. Subjects
Patients recruited to this study were selected from a larger cohort
(the West London First Episode Psychosis study) and had a ﬁrmly
established diagnosis of schizophrenia or schizoaffective disorder
using the DIP-DM Diagnostic Interview for Psychosis (Jablensky,
2000), which includes items from the Operational Criteria Checklist
for Psychosis (OPCRIT) (McGufﬁn et al., 1991) and the WHO Sched-
ules for Clinical Assessment in Neuropsychiatry (SCAN) (Wing et al.,
1990). Substance abuse and dependence were established using the
Alcohol and Drug Use Scales, (Drake et al., 1990). Two research nurses
conducted the interviews, and patients were clinically reviewed by
two experienced consultant psychiatrists (EJ and TB) to conﬁrm the
diagnosis 1 year after inclusion in the study.
Forty-nine patients (36 males, 13 females), mean age 29.9 years
(S.D.±8.74) with diagnoses of schizophrenia (38 patients) or
schizoaffective disorder (11 patients) and a mean illness duration
of 4.4 years (S.D.±3.6) at the time of OCT scanning were recruited.
Forty patients were prescribed antipsychotics (39 atypical and 1 typical),
10 patients were prescribed antidepressants and four mood-stabilising
medication concurrent with an antipsychotic, two were prescribed
mood stabilisers only, one was prescribed night sedation only, and ﬁve
were unmedicated. Scores on the Schedules for the Assessment of Posi-
tive and Negative Symptoms (SAPS and SANS) (Andreasen, 1981;
Andreasen, 1983) were available for a subset of 32 patients. Severity of
negative symptoms ranged from 0 to 16, mean 3.7, and positive symp-
toms ranged from 0 to 10, mean 2.
Forty healthy comparison subjects, matched for age (mean 29.5
years, S.D.±6.12) and gender (25 males, 15 females), were recruited.
All subjects included in the study had a normal ophthalmic
examination including Humphrey 30–2 threshold visual ﬁelds test and
logMAR visual acuity test. There were no differences between groups
in visual ﬁelds: right (t=−0.45, d.f.=73, p=0.66), left (t=−0.58,
d.f.=73, p=0.56) or visual acuity: right (t=1.77, d.f.=76, p=0.08),
left (t=1.76, d.f.=76, p=0.08). In patients the mean visual ﬁelds
(S.D.) were right=−1.11 (1.35), left=−1.15 (1.33) and in controls
right=−1.06 (1.45), left=−1.11 (1.35). In patients the mean visual
acuities (S.D.) were right=0.004 (0.11), left=0.004 (0.12) in controls
right=−0.029 (0.10) and left=−0.029 (0.11). Intraocular pressureswere not recorded, but there was no evidence of optic disc cupping in
any of our subjects.
2.1.1. Exclusion criteria
Exclusion criteria for all subjects were as follows: a) concurrent or
previous systemic disease (e.g. diabetes or autoimmune disease) that
could involve the eyes, b) a history of neurological or ophthalmolog-
ical disease known to affect the visual pathway (e.g. glaucoma), c)
high myopia (b−6D) as this may cause artefactual reduction in
RNFL thickness and difﬁculty in ﬁxation, d) previous head injury
with loss of consciousness, and e) drug or alcohol dependence. Ethical
approval was granted by the Joint Ethics committee of the UCL Insti-
tute of Neurology and University College Hospital NHS Foundation
Trust, and this study was carried out in accordance with The Code
of Ethics of the World Medical Association (Declaration of Helsinki).
2.2. Optical coherence tomography
Using OCT, a cross-sectional image of the retina is produced by
measuring the echo time delay of back-scattered infra-red light
after it has passed into the eye and is bounced back using a low
coherence light source and interferometer. OCT was performed by a
neurologist (MK) trained and experienced in using the Stratus OCT3
device and software (Carl Zeiss Meditec Inc., California, USA) at UCL
Institute of Neurology. RNFL images were acquired for each eye by
taking a circumpapillary scan of 3.4-mm diameter to effectively inter-
cept all nerve ﬁbres converging toward the optic disc while avoiding
inaccurate measurements resulting from peripapillary atrophy
(Schuman et al., 1996).
2.2.1. Retinal nerve ﬁbre layer and macular volume measures
The thickness of the RNFL quadrants (temporal, superior, nasal
and inferior), were calculated by the OCT device software and repre-
sented by a line graph indicating RNFL thickness at all sections of the
scanning circle (Fig. 1). With the Fast RNFL protocol, the mean of
three circular 3.4-mm diameter scans, centred on the optic disc, was
used to express RNFL thickness. MV was measured in each eye by tak-
ing six consecutive radial linear scans centred on the fovea, to provide
six sets of equally spaced and intersecting scans, and to obtain a single
average value (using the fast macular thickness map scanning proto-
col). The Stratus OCT3 device assigns a signal strength (10 being the
maximum) to OCT images. These were rejected if signal strength
was less than 7 or when the difference in signal strength between
images for the two eyes was greater than 2 to ensure consistency in
the quality of scans obtained.
2.3. Statistical analysis
Independent samples t-tests and chi-squared tests were used to
compare age and gender between all patients and controls.
A generalised linear mixed model (GLMM) approach was used to
compare whole retina RNFL thickness, quadrant RNFL thickness and
MV between three groups (controls, schizophrenia patients and schi-
zoaffective disorder patients). Multilevel models were used to
account for the fact that observations within each patient (i.e. right
and left eyes) were not independent, while also controlling for possi-
ble confounding effects of age, gender and disease duration (Laird and
Ware, 1982). Where association was shown between eye and disease
subtype, linear regression analysis was used to investigate the effect
of disease subtype on each eye independently.
In the patient group, multiple linear regression analysis was used
to investigate the relationship between severity of positive and nega-
tive symptoms with measures of RNFL thickness and MV in both eyes,
while controlling for age and gender. Statistical signiﬁcance was
reported at pb0.05.
Table 1
Whole retina RNFL, quadrant RNFL and MV measures within groups.
OCT measures Controls Schizophrenia Schizoaffective
Mean
(95% CI)
Mean
(95% CI)
Mean
(95% CI)
Whole retina RNFL (μm)
Right eye 100.71
(97.49–103.93)
100.90
(97.10–104.70)
97.19
(89.23–105.15)
Left eye 101.24
(97.55–104.94)
99.11
(95.26–102.95)
97.72
(89.66–105.78)
Temporal quadrant RFNL (μm)
Right eye 70.63
(66.45–74.80)
66.08
(62.24–69.91)
70.18
(61.41–78.95)
Left eye 64.50
(61.44–67.56)
67.82
(64.43–71.20)
64.45
(57.01–71.90)
Superior quadrant RNFL (μm)
Right eye 128.03
(123.20–132.85)
125.82
(119.84–131.79)
123.00
(108.00–138.00)
Left eye 127.70
(123.22–132.18)
127.74
(122.26–133.21)
127.45
(111.94–142.97)
Nasal quadrant RNFL (μm)
Right eye 81.53
(76.02–87.03)
88.53
(82.58–94.47)
70.45
(60.96–79.95)
Left eye 83.17
(77.12–89.23)
76.32
(69.76–82.87)
77.55
(69.07–86.02)
Inferior quadrant RNFL (μm)
Right eye 121.53
(116.56–126.49)
124.13
(118.23–130.03)
124.91
(115.06–134.76)
Left eye 124.28
(119.35–129.20)
123.74
(116.80–130.67)
121.55
(112.29–130.80)
Macular volume (mm³)
Right eye 6.81
(6.71–6.92)
6.85
(6.72–6.97)
6.90
(6.65–7.16)
Left eye 6.91
(6.81–7.02)
6.91
(6.78–7.03)
6.96
(6.67–7.24)
Fig. 1. Example of RNFL measurements taken from a healthy eye. Line of graph shows RNFL thickness of the scanning circle as seen around the optic nerve head in the photograph
on the right. X axis = position on scanning circle and Y axis = RNFL thickness at different positions. TEMP 169= temporal, SUP= superior, NAS= nasal, INF = inferior. The colours
represent normal distribution percentiles. Green = 95 to 5%, yellow = 5 to 1%, red = 1 to 0%.
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Power calculation was based on a study reporting subtle decreases
in RFNL thickness in the unaffected eyes of patients with MS due to
subclinical axonal damage (Fisher et al., 2006). We estimated that
in order to detect a mean between-group difference in RNFL thickness
of 9 μm with a standard deviation of ±14 μm and a standardised dif-
ference of 0.64, a sample size of 38 patients and 38 controls would be
needed to achieve an 80% probability of detecting differences between
the two groups at a 5% signiﬁcance level. Based on Henderson et al.
(2008), with a mean difference in MV of 0.27 mm³ between groups,
our sample size would give a 70% probability of detecting a group
difference at the 5% level of signiﬁcance.
3. Results
Patients and controls were matched for age (t=0.27, d.f.=85,
p=0.79) and gender (χ²=0.27, p=0.36). Mean and 95% conﬁdence
intervals for whole retina RNFL, quadrant RNFL and MV measures in
controls, schizophrenia and schizoaffective disorder groups are
reported in Table 1.
3.1. Group comparisons
Using multi-level analyses, patients with schizophrenia or schi-
zoaffective disorder did not differ from controls in whole retina
RNFL or MV measurements (Table 2). The left nasal quadrant RNFL
appeared thinner than the right across all groups and also showed
evidence of an interaction between eye and disease subtype
(p=0.002), with signiﬁcant difference in right but not left nasal
quadrant RNFL thickness between the patient groups. After adjust-
ment, schizoaffective disorder patients had a thinner right nasal
quadrant (mean −17.9 μm, 95% CI=−31.0 to −4.9) than those
with schizophrenia (p=0.02). Left temporal quadrant RNFL appeared
thinner than the right across all groups, and there was an interaction
between side and disease subtype (p=0.009), but there was no
difference in right (p=0.18) or left (p=0.23) temporal quadrant
RNFL thickness between groups.
3.2. Symptom severity
In patients, multiple linear regression showed a moderate associa-
tion between lower MV and positive symptom severity (right β=
−0.54, p=0.02; left β=−0.49, p=0.04). When only those patients
with schizophrenia were included in the analysis, a strong association
was seen (right β=−0.85, p=0.04; left β=−0.85, p=0.05). MV
was not associated with severity of negative symptoms, and RNFL
was not associated with positive or negative symptom severity.4. Discussion
This study did not detect any differences in whole retina RNFL
thickness or MV between patients with schizophrenia or schizoaffec-
tive disorder and healthy controls. These negative ﬁndings suggest
that in patients with schizophrenia or schizoaffective disorder there is
no detectable loss of unmyelinated axons in the retina in the early
years after disease onset. Based on average values from both eyes for
mean and standard deviations of the RNFL thickness of our subjects, a
retrospective sample size calculation showed that at least 300 subjects
would have been required in each arm of the study to detect any signif-
icant differences between groups, had they been present, with 80%
Table 2
Multi-level analyses of whole retina RNFL, quadrant RNFL and MV.
Unadjusted analysis Adjusted analysis
Whole retina RNFL Regression coefﬁcient (95% CI) p-value Regression coefﬁcient (95% CI) p-value
Disease type: 0.63 0.86
Control Ref Ref
Schizophrenia −0.97 (−5.79, 3.85) −0.78 (−5.58, 4.03)
Schizoaffective disorder −3.52 (−10.76, 3.73) −1.93 (−9.32, 5.47)
Eye; left versus right −0.46 (−1.78, 0.86) 0.50 −0.46 (−1.78, 0.86) 0.50
Age; for each 1 year older −0.38 (−0.66, −0.10) 0.008 −0.38 (−0.67, −0.08) 0.01
Gender; male versus female −2.72 (−7.54, 2.10) 0.27 −3.13 (−8.13, 1.87) 0.22
Disease duration; for each year longer −1.01 (−1.85, −0.16) 0.02 – –
Temporal quadrant RNFL
Disease type: 0.96 0.79
Control Ref Ref
Schizophrenia −0.62 (−4.91, 3.68) −1.33 (−5.76, 3.10)
Schizoaffective disorder −0.24 (−6.70, 6.21) 0.68 (−6.14, 7.50)
Eye; left versus righta −2.72 (−5.28, −0.16) 0.04 −2.72 (−5.28, −0.16) 0.04
Age; for each 1 year older −0.00 (−0.26, 0.26) 0.99 −0.01 (−0.29, 0.26) 0.92
Gender; male versus female 2.66 (−1.61, 6.93) 0.22 3.19 (−1.42, 7.80) 0.18
Disease duration; for each year longer −0.65 (−1.37, 0.06) 0.07 – –
Superior quadrant RNFL
Disease type: 0.87 0.83
Control Ref Ref
Schizophrenia −1.09 (−8.02, 5.85) −2.10 (−9.22, 5.01)
Schizoaffective disorder −2.64 (−13.06, 7.79) 0.36 (−10.58, 11.31)
Eye; left versus right 1.22 (−1.48, 3.93) 0.37 1.22 (−1.48, 3.93) 0.38
Age; for each 1 year older −0.34 (−0.76, 0.07) 0.10 −0.36 (−0.81, 0.08) 0.11
Gender; male versus female 2.09 (−4.86, 9.03) 0.56 2.52 (−4.89, 9.92) 0.51
Disease duration; for each year longer −1.75 (−3.00, −0.49) 0.006 – –
Nasal quadrant RNFL
Disease type: 0.25 0.52
Control Ref Ref
Schizophrenia 0.07 (−6.91, 7.05) −0.40 (−7.61, 6.82)
Schizoaffective disorder −8.35 (−18.84, 2.14) −6.39 (−17.49, 4.72)
Eye; left versus righta −3.60 (−7.56, 0.37) 0.08 −3.60 (−7.56, 0.37) 0.08
Age; for each 1 year older −0.37 (−0.79, 0.05) 0.09 −0.29 (−0.74, 0.16) 0.21
Gender; male versus female 1.73 (−5.36, 8.83) 0.63 0.45 (−7.06, 7.96) 0.91
Disease duration; for each year longer −1.19 (−2.36, −0.02) 0.05 – –
Inferior quadrant RNFL
Disease type: 0.96 0.94
Control Ref Ref
Schizophrenia 1.03 (−5.98, 8.05) 0.95 (−6.31, 8.20)
Schizoaffective disorder 0.33 (−10.22, 10.87) 1.79 (−9.37, 12.94)
Eye; left versus right 0.65 (−2.20, 3.51) 0.65 0.65 (−2.20, 3.51) 0.66
Age; for each 1 year older −0.26 (−0.68, 0.16) 0.22 −0.28 (−0.73, 0.17) 0.23
Gender; male versus female −1.06 (−8.09, 5.97) 0.77 −1.24 (−8.79, 6.30) 0.75
Disease duration; for each year longer −0.65 (−1.95, 0.66) 0.33 – –
MV
Disease type: 0.85 0.64
Control Ref Ref
Schizophrenia 0.01 (−0.14, 0.16) 0.00 (−0.16, 0.16)
Schizoaffective disorder 0.07 (−0.16, 0.30) 0.11 (−0.13, 0.36)
Eye; left versus rightb 0.08 (0.05, 0.11) b0.0001 0.08 (0.05, 0.11) b0.0001
Age; for each 1 year older −0.00 (−0.01, 0.01) 0.46 −0.00 (−0.01, 0.01) 0.34
Gender; male versus female 0.04 (−0.12, 0.19) 0.63 0.06 (−0.11, 0.22) 0.51
Disease duration; for each year longer −0.04 (−0.07, −0.01) 0.005 – –
a Quadrant RNFL thinner in left than right eye.
b MV smaller in left eye but no evidence for interaction between eye and disease type (p=0.47).
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this OCT methodology, RNFL variations are too subtle to be of value
as a biological marker for schizophrenia.
Differences in RNFL thickness were seen in the right nasal quad-
rant between patients with schizophrenia and schizoaffective disorder.
Differences in temporal quadrant RNFL, however, were not associated
with disease subtypes. These unexpected results cannot be explained
by age or gender differences and should be interpreted with caution
given the small number of patients with schizoaffective disorder in
this study. Possible medication effects cannot be excluded, as half of
the schizoaffective patients were also prescribed antidepressants or
mood stabilisers as adjuncts to atypical antipsychotics.
The association between severity of positive symptoms and MV in
patients with schizophrenia needs replicating in a larger sample as itmay represent state-dependent abnormalities similar to those reported
by an ERG study (Balogh et al., 2007) that described transient retinal
changes (i.e. decreased amplitude of the a-wave indicative of altered
early visual information processing) that which during acute relapses
correlated with the severity of positive symptoms and were attributed
to state-dependent alterations in phospholipid metabolism and/or
impaired dopaminergic transmission.
Our results also suggest that axonal damage may be less important
than myelin abnormalities in explaining the frequently reported
reductions in brain volume in schizophrenia. There is growing
evidence for disruption of white matter integrity in the early stages of
schizophrenia (Price et al., 2006, 2007; Pérez-Iglesias et al., 2010),
which lends support to this possibility. The negative ﬁndings are also
in keeping with our earlier studies in patient samples overlapping the
93E.M. Chu et al. / Psychiatry Research: Neuroimaging 203 (2012) 89–94one described here, which failed to demonstrate differences in corti-
cal volume between patients and controls using surface-based mor-
phometry (Gutiérrez-Galve et al., 2010) and only fronto-temporal
white matter volume loss with no cortical changes observed when
using magnetization transfer imaging or volumetric MRI (Price et al.,
2006).
The main limitation of this study is low OCT resolution, which may
be inadequate to detect the subtle abnormalities that may be present
in the early years of schizophrenia. Transverse resolution can reach a
maximum of 10 μm in tissue and 15 μm in air using the Stratus OCT
device (Fujimoto et al., 2004); hence, sensitivity is too low to visualise
individual axons, which are typically 1 μm in diameter. This point has
been made by Naismith et al. (2009), who detected RNFL thinning in
optic neuritis in only 60% of cases, and detection rates were lower in
those with good recovery. Newer technology using spectral domain
OCT is faster and offers better axial resolution (5 μm compared to
10 μm) and more accurate macular thickness measurement than the
Stratus OCT3 device used in our study.
Most of our patients were receiving atypical antipsychotic medica-
tion at the time of data collection, and it is impossible to exclude the
potential neuroprotective effects of these drugs (Navari and Dazzan,
2009), which may have obscured minor differences in RNFL between
the groups.
Despite mainly negative ﬁndings from this ﬁrst exploratory study,
there is a need for further OCT investigations to examine possible
RNFL thinning and decreased MV in schizophrenia patients with
longer illness duration. A longitudinal study would additionally be
able to detect whether progressive retinal changes occur, at which
stage of the disease this may happen and whether these retinal
measures could be utilised as a trait or state marker of schizophrenia
or schizoaffective disorder.
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